MaxCyte signs multi-platform technology license deal with Genentech to support cell therapy development

Reuters2026/07/21 12:08

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MaxCyte entered a technology license partnership with Genentech to support development of multiple cell therapy programs.
License gives Genentech access to MaxCyte’s ExPERT GTx platform across select research, clinical development, manufacturing workflows.
Deal targets ex vivo cell-engineering applications, aiming to streamline progress from early discovery through cGMP manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210805PRIMZONEFULLFEED9764808) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MaxCyte signs multi-platform technology license deal with Genentech to support cell therapy development

You may also like

Crypto prices